Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
Kevin CowartNicholas W CarrisPublished in: Expert opinion on pharmacotherapy (2020)
In patients with type 2 diabetes and ASCVD, ertugliflozin appears safe with a noted non-significant trend toward improved renal outcomes. Approximately 23.7% of patients in the VERTIS-CV trial had heart failure, the highest among SGLT-2 inhibitor CVOTs. The VERTIS-CV trial reaffirms the reduction in heart failure hospitalizations as a likely class effect of SGLT-2 inhibitors. While the trial supports the use of ertugliflozin beyond glycemic control, agents with confirmed superiority for improved cardiovascular outcomes and mortality may be preferred.
Keyphrases
- heart failure
- phase iii
- glycemic control
- study protocol
- phase ii
- clinical trial
- type diabetes
- end stage renal disease
- ejection fraction
- newly diagnosed
- left ventricular
- cardiovascular disease
- prognostic factors
- adipose tissue
- skeletal muscle
- patient reported outcomes
- cardiac resynchronization therapy
- patient reported